PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Burrill invests in Taiwan Liposome

US venture capital firm Burrill has invested in Taiwan Liposome, a Taiwan-based pharmaceutical company with operations in Taipei and South San Francisco.

US venture capital firm Burrill has invested in Taiwan Liposome, a Taiwan-based pharmaceutical company with operations in Taipei and South San Francisco.

Taiwan Liposome’s lead product, ProFlow, is used to treat peripheral arterial disease and diabetic neuropathy and is currently undergoing product development and registration in Asian markets.

The company’s ovarian and breast cancer treatment, Lipo-Dox, is already marketed in Taiwan.

"We believe that Taiwan Liposome’s core advantage of applying proprietary drug delivery technology to extend product lifecycles with performance improvements enables Taiwan Liposome to develop and commercialize new formulations of products with significant market potential," says Burrill general partner Dr. Ann Hanham.

"It is exciting and stimulating for Taiwan Liposome to have Burrill as a new addition to our current investors. We will benefit greatly from Burrill’s extensive international experience and expertise, elevating Taiwan Liposome to becoming a global biotechnology company," says Taiwan Liposome chairman Dr. Keelung Hong.

Burrill was joined in this series A round of financing by YFY Biotech Management, TaiAn Technologies Eminent, Boston Life Science Venture, and other earlier investors. The proceeds will serve to advance the development of its lead product and prepare the company for an IPO in Taiwan.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured